The three-year project funded by the Engineering and Physical Sciences Research Council (EPSRC) and led by Professor Rob Short FTSE and Professor Nick Turner, will use Cold Atmospheric Plasma (CAP) and molecular imprinting to deliver precision treatments for glioblastoma, autoimmune disease, and invasive fungal infections.